Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen
Executive Summary
Analysts call Intercept sell-off overblown in wake of EASL presentation of fuller Phase III data for OCA in NASH. But while depth is added to efficacy argument, pruritus concerns possibly worsen.
You may also be interested in...
Metacrine Choosing Between Two NASH FXR Agonists It Calls Best-In-Class
Biotech is determining which of its mid-stage FXR candidates – MET409 and MET642 – will offer the best overall profile to take into Phase IIb. It is also studying ‘409 in combination with Jardiance and will test the FXR class in inflammatory bowel disease.
Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business And Investment
Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.
Galectin’s NASH Phase III Trial Will Use Surrogate Measures Of Esophageal Varices
Other NASH registration trails have targeted fibrosis, but Galectin's mostly-resolved discussions with US FDA will allow the belapectin program to focus of signs and symptoms of the disease.